Oncogenic signaling by Kit tyrosine kinase occurs selectively on the Golgi apparatus in gastrointestinal stromal tumors

Yuuki Obata(The Francis Crick Institute), Ryo Abe(Tokyo University of Science), Hiroyasu Esumi(National Cancer Center Hospital East), Masahiko Tsujimoto(Osaka Police Hospital), Keita Horikawa(Tokyo University of Science), Tsuyoshi Takahashi(The University of Osaka), Yuki Akieda(Gunma University), Jonathan A. Fletcher(Harvard University), Toshirou Nishida(National Cancer Center)
Oncogene
February 13, 2017
10.1038/onc.2016.519
Cited by 47

Related Papers

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
|The Lancet|2012|1.4k
TPM3-ALK and TPM4-ALK Oncogenes in Inflammatory Myofibroblastic Tumors
|American Journal Of Pathology|2000|716
STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications
|Oncogene|2001|700
KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal Tumors
|American Journal Of Pathology|2000|647
Primary Renal Neoplasms with the ASPL-TFE3 Gene Fusion of Alveolar Soft Part Sarcoma
|American Journal Of Pathology|2001|639